Harvard Medical School, Boston, MA, USA; Multidisciplinary Eating Disorders Research Collaborative, Mass General Brigham, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Stockholm, Sweden.
Contemp Clin Trials. 2023 Nov;134:107336. doi: 10.1016/j.cct.2023.107336. Epub 2023 Sep 16.
Avoidant/restrictive food intake disorder (ARFID) symptoms are common (up to 40%) among adults with functional dyspepsia (FD), a disorder of gut-brain interaction characterized by early satiation, post-prandial fullness, epigastric pain, and/or epigastric burning. Using an 8-session exposure-based cognitive-behavioral treatment (CBT) for adults with FD + ARFID compared to usual care (UC) alone, we aim to: (1) determine feasibility, (2) evaluate change in clinical outcomes in, and (3) explore possible mechanisms of action.
We will randomize adults with FD who meet criteria for ARFID with ≥5% weight loss (N = 50) in a 1:1 ratio to CBT (with continued UC) or to UC alone. A priori primary benchmarks will be: ≥75% eligible participants enroll; ≥75% participants complete assessments; ≥70% participants attend 6/8 sessions; ≥70% of sessions have all content delivered; ≥70% participants rate Client Satisfaction Questionnaire scores above scale midpoint. We will also examine the size of changes in FD symptom severity and related quality of life within and between groups, and explore possible mechanisms of action.
Findings from this trial will inform next steps with treatment development or evaluation-either for further refinement or for next-step efficacy testing with a fully-powered clinical trial.
在功能性消化不良(FD)患者中,回避/限制型食物摄入障碍(ARFID)症状较为常见(高达 40%),这是一种胃肠道-大脑相互作用障碍,其特征为早饱、餐后饱胀、上腹痛和/或上腹部烧灼感。我们采用 8 次基于暴露的认知行为治疗(CBT)对 FD+ARFID 成人患者进行治疗,并与单独接受常规护理(UC)进行比较,旨在:(1)确定可行性;(2)评估治疗后临床结局的变化;(3)探索可能的作用机制。
我们将以 1:1 的比例随机分配符合 ARFID 标准且体重减轻≥5%的 FD 成人患者(N=50)至 CBT(同时继续接受 UC)或单独接受 UC。预先设定的主要基准为:≥75%的合格参与者入组;≥75%的参与者完成评估;≥70%的参与者参加 6/8 次治疗;≥70%的治疗课程提供了所有内容;≥70%的参与者对客户满意度问卷评分的评价高于量表中点。我们还将检查 FD 症状严重程度和相关生活质量在组内和组间的变化幅度,并探索可能的作用机制。
该试验的结果将为治疗方法的进一步开发或评估提供信息,无论是为了进一步改进,还是为下一阶段的疗效测试提供更全面的临床试验。